Navigation Links
VICRYL (polyglactin 910) woven mesh

ProductsVICRYL (polyglactin 910) woven mesh
Company Ethicon, Inc.
Item VICRYL (polyglactin 910) woven mesh
Features 
  • Provides a more occlusive wrap than VICRYL knitted mesh
  • Especially suitable for injuries where wound transudate must be contained
  • Predictable absorption
  • Polyglactin 910 has been found to be inert, nonantigenic, and nonpyrogenic
    • Description Provides a more occlusive wrap than VICRYL knitted mesh. Especially suitable for injuries where wound transudate must be contained. Predictable absorption. Polyglactin 910 has been found to be inert, nonantigenic, and nonpyrogenic. VICRYL (polyglactin 910) woven mesh is prepared from a synthetic absorbable copolymer of glycolide and lactide, derived respectively from glycolic and lactic acids. This tightly woven mesh is prepared from uncoated, undyed fiber identical in composition to that used in VICRYL (polyglactin 910) synthetic absorbable suture, which has been found to be inert, nonantigenic, nonpyrogenic and to elicit only a mild tissue reaction during absorption. VICRYL woven mesh is intended for use as a buttress to provide temporary support during the healing process.
    Info Ethicon, Inc.
    Customer Service: (800) 4-ETHICON
    Web site: http://www.ethicon.com/

    Related medicine products :

    1. VICRYL (polyglactin 910) knitted mesh
    2. ENDOLOOP Ligature Type - 0 Coated VICRYL®
    3. ENDOLOOP Suture Type - 0 Coated VICRYL
    4. ENDOKNOT Suture Type - 0 Coated VICRYL
    5. Clo-Sur P.A.D. Nonwoven Hydrophilic Wound Dressing
    Other Medicine News:Health News:Video: Grin Big With an Award-Winning Smile 2Health News:Video: Grin Big With an Award-Winning Smile 3Health News:Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years 2Health News:Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years 3Health News:Pharmos Restructures Operations in Israel 2Health News:Pharmos Restructures Operations in Israel 3Health News:Ranbaxy Receives Tentative Approval For Valsartan Tablets 2Health News:TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock 2Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 2Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 3Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 4Health News:Merge Healthcare Provides Update on the Restatement of Its Financial Statements 5
    Breaking Medicine Technology:Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4New Executive Leadership and CEO Announced for BiPar Sciences 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Women 26apos 3Bs Pelvic Organ Prolapse and Incontinence Guide Informs Outlines Treatments 57906 1Women 26apos 3Bs Pelvic Organ Prolapse and Incontinence Guide Informs Outlines Treatments 57906 2Women 26apos 3Bs Pelvic Organ Prolapse and Incontinence Guide Informs Outlines Treatments 57906 3Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians 57903 1Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians 57903 2Link High Technologies to Offer Allscripts MyWay Affordable Electronic Health Records to NJ Physicians 57903 3Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 1Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 2Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 3Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 4Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 5Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 6Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improves Progression Free Survival in Second Line Metastatic Colorectal Cancer 5028 8